Welcome

Pre-Open

RMi Pre-opening: Another econ and a deferred tariff legal ruling

January 9, 2026

Nonfarm payrolls likely will rise by 73,000 <December’s> while the unemployment rate edges lower to 4.5% <consensus reporting to be released at 8:30 a.m. ET>

Deferred... the Supreme Court’s opinions on the legality of tariffs imposed by Trump was expected

Pre-open Signals: 3 Positive and 1 Negative with many non-pre-open indications; If you understand probabilities, the inevitable is easier to maneuver

Never leave retail investor uninformed … I say what others won’t, so you can do what others can’t!

RMi Research Note: Capricor Therapeutics (CAPR) DUMP before the next big SLUMP!

January 9, 2026

DON’T be distracted – CONTINUE the SELL into strength, right yet again, let's NOT be a set-up for a PONZI schematic?

Continuous declines are here soon to stay; timing will be everything until the FDA “speaks;” the higher CAPR rose from 12/2’s $6.36, the steeper the fall!

STICKING to my CONVICTION that Capricor Therapeutics (CAPR) is overbought and whose valuation is disconnected from fundamentals.

RMi Closing Bell: Econs affect a winning session with sector weakness

January 9, 2026

The biotech and C&GT sector spirals into negative trading with alternating and “spurious” multiples that present a popular “outing” as the JP Morgan healthcare Conference kicks-off while major risk LPS (loss-per-share) will factor-in before Q4 and FY25 earnings expectation

Pre-open Signal Results: 3 Hit and 1 Miss

RMi collects, curates, interprets and disseminates cell and gene therapy sector (C&GT) fact-based news, trustable and verified intel of share pricing data bridging the gap to an investment decision

Never leave a retail investor uninformed! It’s not always time to buy or sell; but it is time to KNOW why!

I chose to speak-up when many analysts, brokers and commentators have shut-up!

RMi Research Note: Capricor Therapeutics (CAPR) DUMP before the next big SLUMP!

January 9, 2026

For all my … <some say> … RANTINGS, I say TRUTH … closed DOWN -$1.71 or -6.99% with 2.592 M shares traded after Thursday's -$0.76 or -2.89% to $25.55 after Wednesday (1/7) was UP +$0.18; their I Banks are executing the “PUMP” to protect the offering share pricing after being stripped of value in past sessions DON’T be distracted – CONTINUE the SELL into strength, right yet again, let's NOT be a set-up for a PONZI schematic? Continuous declines are here soon to stay; timing will be everything until the FDA “speaks;” the higher CAPR rose from 12/2’s $6.36, the steeper the fall! STICKING to my CONVICTION that Capricor Therapeutics (CAPR) is overbought and whose valuation is disconnected from fundamentals.

RegMedInvestors (RMi) Financing Note: Arrowhead Pharmaceuticals (ARWR) priced its offerings of notes, stock and warrants

January 8, 2026

Of $625 M aggregate principal amount of 0.00% convertible senior notes due 2032 and 3,100,776 shares of common stock, at a public offering price of $64.50 per share and pre-funded warrants, at an offering price of $64.499 per pre-funded warrant, for up to 1,550,387 shares of common stock ARWR is up +$1.14 or +1.74% to $66.85 Getting it done while it can and still with a positive response